www.hivandhepatitis.com

Back HCV Disease Progression

Brivanib Does Not Improve Liver Cancer Survival for Treatment-Experienced Patients

Details
Category: Liver Cancer/HCC
Published on Tuesday, 03 January 2012 00:00
Written by Press Release
  • Print

Bristol-Meyers Squibb's investigational anti-cancer drug brivanib did not improve overall survival of patients with hepatocellular carcinoma (HCC) who were unable to take or did not respond to sorafenib (Nexavar) in the Phase 3 BRISK-PS trial, the company recently reported. The drug is still being tested in other patients populations.

Read more:

More Articles...

  1. EACS 2011: Antiretroviral Therapy Reduces Liver Fibrosis Progression in HIV/HCV Coinfected People
  2. ICAAC 2011: Interferon May Reduce Liver Disease Progression in HIV/HCV Coinfected Relapsers
  3. ICAAC 2011: Didanosine, Higher HCV Viral Load Predict Liver Fibrosis in HIV/HCV Coinfected People
  4. HCV Can Be Sexually Transmitted Between HIV+ Men
  5. Gene Variation Linked to Liver Cancer in Hepatitis C Patients

Subcategories

Copyright © 2025 www.hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com. Joomla! is Free Software released under the GNU General Public License.

Bread and Roses Web DesignWeb Design and Development by Bread and Roses Web Design